# Q500B verification review 2: s83 revision 2, Toxicology (tox-48 to tox-52)

Reviewer: Preceptor independent QA, fresh reviewer. I did not write, edit or review this batch before, and I changed nothing in it (REVIEW-RULES rule 1). All items stay `reviewed: false`.

Read first: Q500B_BRIEF.md (Independent QA), REVIEW-RULES.md, SCORING-RULINGS.md, SAMP_REVIEW_BRIEF.md, the first review (q500b-qa-s83.md), the first verification (q500b-verify-s83.md) and the writer's report with its "Revision 1" and "Revision 2" sections (q500b-writer-s83.md). I reviewed the whole final batch, not only the changes.

## Tests

`SAMP_BATCH=s83 npx vitest run tests/samps.test.ts tests/samp-quality.test.ts tests/citations.test.ts --testTimeout=120000`: 132 of 132 pass (bank-wide near duplicate stem test 8.8 s).

House style, checked by script: no em or en dashes and no semicolons in content strings. Canadian spelling ("labour", "counsellor", "centred", "Paediatric"). No mnemonics. No personal names outside citations.

Counts recomputed: 21 questions, 20 single and 1 menu. Key features kf1 3, kf2 1, kf3 2, kf4 3, kf5 1, kf6 1, kf7 2, kf8 8, all covered. Single key positions 0 to 4: 5, 3, 5, 5, 2. These match Revision 2.

## Earlier fails: resolution

| Item | Earlier fail | Status |
|---|---|---|
| tox-48 q2 (first review) | 4 hour untreated gap, BP option not in the case, unclear sentence | Resolved. "Thirty minutes later, while his IV is being placed", option "BP of 158/94 mmHg", sentence reworded. |
| tox-49 q2 (first review) | Update revealed the q1 glucose key, Finnegan wording | Resolved. Update deleted, Finnegan sentence as asked. |
| tox-50 q5 (first review) | Update revealed the q4 key | Resolved. q5 deleted, teaching at the end of q4 with correct numbers. |
| tox-51 q3 (first review) | Gliclazide update revealed q1 and q2 keys, octreotide key decision repeated | Resolved. Octreotide question gone. No update names the sulfonylurea or the home search result. |
| tox-49 q3 (verification) | Update restated the ESC criteria that are the q2 key | Resolved. Update now "Over the next 2 hours he feeds poorly and cries most of the time, even when his mother holds him." No ESC structure or thresholds. Explanation now "He is feeding poorly and cannot be settled". |
| tox-51 q4 (verification) | Update named norepinephrine, the q3 key | Resolved. Update now "on a vasopressor infusion". |

Optional changes in Revision 2, judged on merits (REVIEW-RULES rule 4): tox-48 q1 last sentence shortened (fine). tox-49 stem gains "There are no focal neurological signs." (fine, supports the q1 explanation). tox-51 q1 sentence replaced (introduces a gap, see the fail below).

## Verdicts by question

| SAMP | Q | Verdict | Finding and exact fix | Confidence |
|---|---|---|---|---|
| tox-48 | q1 | FAIL | Mock-mode cue (ruling B6) not raised in earlier rounds. Three later prompts say "his withdrawal": q2 "best shows that his withdrawal has become severe", q3 "initial treatment for his withdrawal" and q5 "a complication of his withdrawal". Shown at once in mock mode, they remove serotonin toxicity, sympathomimetic toxicity and thyrotoxic crisis from the q1 options and leave alcohol withdrawal (which the stem excludes, he does not drink) against the key. Fix: q2 prompt "Which of the following findings best shows that his condition has become severe?". q3 prompt "Which of the following is the most appropriate initial treatment for him?". q5 prompt "Which of the following investigations is most important to look for a complication of his condition?". Explanations may keep "withdrawal". Clinical content of q1 is correct: Tay 2022 (verified) calls GBL an industrial solvent, half-life and onset per Weaver. | medium |
| tox-48 | q2 | PASS | Delirium with hallucinations marks severe withdrawal (Tay 2022, verified: "Acute delirium, visual or auditory hallucinations and seizures have been reported in severe GHB withdrawal"). Pulse 118 to 112 checks. Minor: Tay does not mention craving, but "craving is common in mild withdrawal" is uncontroversial. | |
| tox-48 | q3 | PASS | Benzodiazepine first line (Weaver). Neuroleptics "trialled with variable success" (Tay, verified). Single key. Prompt wording is part of the q1 fail. | |
| tox-48 | q4 | PASS | Barbiturate "to good effect after failure of benzodiazepine treatment" (Tay, verified), phenobarbital with high-acuity monitoring (Weaver). "First-line drug class" in the update names no drug, an accepted compromise. | |
| tox-48 | q5 | PASS | "Seizures and rhabdomyolysis each occurred in 7% of cases" (Wojtowicz abstract, verified). Prompt wording is part of the q1 fail. | |
| tox-49 | stem | PASS | Discharge at 96 hours fits a longer-acting opioid. Day 5 with 1 day of symptoms agrees. Weight 3.4 to 3.1 kg is 8.8%. | |
| tox-49 | q1 | PASS | Capillary glucose first. Explanation now traces to the stem (flat fontanelle, no focal signs). | |
| tox-49 | q2 | PASS | ESC recommended by CPS. No later update now restates ESC criteria. | |
| tox-49 | q3 | PASS | Ward admission with rooming in, non-drug care first, morphine second, phenobarbital not first line. Revised update and explanation agree with each other. | |
| tox-49 | q4 | PASS | Breastfeeding conditions met (HIV negative, on OAT, no other substances). | |
| tox-50 | q1 | PASS | Anticholinergic toxidrome, each distractor reason true. | |
| tox-50 | q2 | PASS | | |
| tox-50 | q3 | PASS | 1 g/kg at 52 kg is 52 g, 50 g fine. 4 hour window per Dart 2023 (verified in full text by the previous reviewer). | |
| tox-50 | q4 | PASS | Recomputed at 6.62 umol/L per mg/L: 480 is 72.5 mg/L, 1000 is 151 mg/L, 66 is 10 mg/L, 690 is 104 mg/L, 75 mg/L is 497 umol/L. The stated dose of 24 extra strength tablets is 12 g, about 231 mg/kg, which is consistent with a level that may still rise. Repeat level 4 to 6 hours after the first with an anticholinergic co-ingestant (Dart 2023). | |
| tox-51 | q1 | FAIL | Revision 2 removed the only sentence that gave a reason for rejecting the distractor "Amlodipine toxicity". The explanation now says twice that refractory hypoglycemia is the sulfonylurea pattern (sentences 1 and 2 repeat each other) but never says why amlodipine itself does not explain it (Lens B8, every distractor needs a true reason). Fix: replace the second sentence ("Hypoglycemia that keeps returning on a dextrose infusion is the pattern of a sulfonylurea, so this unexpected result points to a second drug taken with her amlodipine.") with "Amlodipine toxicity explains her low blood pressure, but it would not explain a glucose that keeps falling on a dextrose infusion, so this unexpected result points to a second drug." If the writer wants to state that calcium channel blocker poisoning tends to raise glucose, a real source exists: Levine M, Boyer EW, Pozner CN, et al. Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007 (PMID 17855820, verified through PubMed eutils), but it studied verapamil and diltiazem only, so the sentence must not claim it for amlodipine. Key itself correct: Glatstein 2012 (verified) describes sulfonylurea hypoglycemia that responds poorly to IV dextrose. | medium |
| tox-51 | q2 | PASS | Low-confidence note carried from the last round: "identify the cause of her low glucose" with "Check all medicines in the home" leans toward a second drug but names none. | low |
| tox-51 | q3 | PASS | St-Onge 2017 (verified): norepinephrine preferred in vasodilatory shock (1D), suggests not to use dopamine in shock, calcium gluconate 3 to 6 g. Glucagon and methylene blue not recommended or suggested. | |
| tox-51 | q4 | PASS | St-Onge 2017 (verified): high dose insulin with other first-line treatment if myocardial dysfunction is present (1D). Update no longer names the q3 key. | |
| tox-52 | q1 | PASS | PAWSS recomputed: threshold met, intoxicated in 30 days 1, past withdrawal 1, autonomic signs 1, total 3. | |
| tox-52 | q2 | PASS | CRISM 2023 recommendation 6 (verified by both earlier reviewers). | |
| tox-52 | q3 | PASS | Blackouts, withdrawal seizures and benzodiazepine with alcohol in 90 days are PAWSS items. The others are not. Two items lift 3 to 5. Note: signed tox-15 q2 (s18) accepts "heavy daily drinking over a long period" as a risk factor for complicated withdrawal. tox-52 does not contradict it, because it asks only about PAWSS items and says the other details "matter to his long term care". | |
| tox-52 | q4 | PASS | CRISM recommendation 7 and its outpatient exception stated correctly. | |

## SAMP verdicts

| SAMP | Verdict |
|---|---|
| tox-48 | FAIL (q1, mock-mode cue from later prompts) |
| tox-49 | PASS |
| tox-50 | PASS |
| tox-51 | FAIL (q1, distractor without a reason) |
| tox-52 | PASS |

## Overlap (whole bank, keyword search)

Searched src/samps and src/cases, including s72 to s88 and batch16 to batch20, for butyrolactone, GHB withdrawal, wheel cleaner, Eat Sleep Console, Finnegan, neonatal abstinence, neonatal opioid withdrawal, rooming in, PAWSS, Withdrawal Severity Scale, gabapentin, high dose insulin, amlodipine, gliclazide, diphenhydramine, co-ingestant, repeat level, alcohol withdrawal, outpatient and CRISM.

- GHB withdrawal, neonatal opioid withdrawal, ESC and PAWSS: no hits outside s83. New.
- Alcohol withdrawal: tox-15 (s18) asks risk factors for complicated withdrawal (write-in) and CIWA signs. s08 delirium-agitation, s16 seizures and batch08 "severe-alcohol-withdrawal" cover delirium tremens, seizures and inpatient benzodiazepine treatment. None tests PAWSS scoring, collateral that changes the score, or outpatient gabapentin for low risk. tox-52 is distinct. tox-52 q3 is a mild echo of tox-15 q2 (past seizures and benzodiazepine use as risk factors), seen through a new angle. Pass.
- Gliclazide: s44 (triage level), batch13 "boarder-hard-to-wake" (octreotide for in-hospital gliclazide), tox-14, s07, s16. None is a hidden sulfonylurea behind a calcium channel blocker overdose.
- Diphenhydramine hits in new batches (s72, s77, batch17) are sedation, agitation and anaphylaxis uses. No acetaminophen repeat-level overlap.
- High dose insulin: tox-04 (s18) and the batch07 calcium channel blocker case, as flagged for the physician in the last round.
- No contradiction of a signed-off item or a SCORING-RULINGS entry. The batch has no write-in match phrases.

## Sources

Verified by me with WebFetch this round:
- St-Onge Crit Care Med 2017, https://pmc.ncbi.nlm.nih.gov/articles/PMC5312725/ : high dose insulin with myocardial dysfunction (1D), norepinephrine in vasodilatory shock (1D), dopamine not suggested in shock, calcium gluconate 3 to 6 g. It does not say that calcium channel blocker poisoning lowers insulin or raises glucose.
- Tay Subst Abuse Rehabil 2022, dovepress URL: GBL an industrial solvent, delirium, hallucinations and seizures in severe withdrawal, neuroleptics with variable success, barbiturates after benzodiazepine failure.
- Wojtowicz CJEM 2008, Cambridge URL: seizures and rhabdomyolysis each 7%.
- Glatstein Clin Toxicol 2012, PubMed 23046209 (abstract through eutils, the PubMed page itself returned a cookie wall): prolonged sulfonylurea hypoglycemia that responds poorly to IV dextrose, octreotide 50 mcg every 6 hours in adults.
- Levine Crit Care Med 2007, PubMed 17855820 (eutils): offered for the tox-51 q1 fix only.

Could not open this round (not guessed):
- CPS 2025, https://cps.ca/en/documents/position/nas-nows : bot verification page again. Europe PMC search returned 503. ESC, rooming in, morphine dose, breastfeeding conditions and the observation window rest on the first review's verification.
- Not reopened, relying on the two earlier reviews that verified them: Weaver CMAJ 2023 (PMC10241545), Dart JAMA Netw Open 2023 (full text verified in the last round), Wood CMAJ 2023 CRISM (PMC10581718). Maldonado Alcohol 2014 has no URL. PAWSS items checked against the published scale.

## Needs physician decision

- Carried over: tox-51 q3 and q4 echo tox-04 and the batch07 calcium channel blocker case (echo-guided vasopressor and insulin choice).
- Carried over: CPS 2025 page not reopened by the last two reviewers. Confirm the 96 hour discharge wording and ESC statements against the CPS text.

## Summary

21 questions reviewed: 19 pass and 2 fail. All six earlier fails (four from the first review, two from the verification) are resolved. The two new fails: tox-48 q1 is cued in mock mode by three later prompts that say "his withdrawal" (three one-word prompt edits), and tox-51 q1 lost its reason for rejecting "Amlodipine toxicity" in Revision 2 (one sentence to replace). No key is clinically wrong, and every number and score recomputed correctly.

Overall: FAIL (2 items)
